Market closedNon-fractional

RAPT Therapeutics/RAPT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Ticker

RAPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

126

RAPT Metrics

BasicAdvanced
$95M
Market cap
-
P/E ratio
-$3.08
EPS
0.52
Beta
-
Dividend rate
$95M
0.52
7.009
6.688
2.916
4.833
-39.60%
-67.21%
0.72
0.72
-0.986
15.30%
10.28%

What the Analysts think about RAPT

Analyst Ratings

Majority rating from 11 analysts.
Hold

RAPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$31M
-0.97%
Profit margin
0.00%
NaN%

RAPT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.26%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.82
-$0.80
-$0.79
-
Expected
-$0.78
-$0.75
-$0.86
-$0.81
-$0.71
Surprise
-15.57%
8.86%
-6.85%
-2.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for RAPT Therapeutics stock?

RAPT Therapeutics (RAPT) has a market cap of $95M as of July 06, 2024.

What is the P/E ratio for RAPT Therapeutics stock?

The price to earnings (P/E) ratio for RAPT Therapeutics (RAPT) stock is 0 as of July 06, 2024.

Does RAPT Therapeutics stock pay dividends?

No, RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next RAPT Therapeutics dividend payment date?

RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders.

What is the beta indicator for RAPT Therapeutics?

RAPT Therapeutics (RAPT) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell RAPT Therapeutics stock

Buy or sell RAPT Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing